Anti-Coagulants - Malaysia

Malaysia

The Anti-Coagulants market in Malaysia is expected to witness significant growth in the coming years.
According to projections, the revenue in this market is estimated to reach US$45.26m in 2024.
Furthermore, a steady annual growth rate of 8.05% is anticipated from 2024 to 2029, leading to a market volume of US$66.66m by the end of 2029.
In terms of global comparison, it is worth noting that United States is expected to generate the highest revenue in the Anti-Coagulants market, with an estimated value of US$16,740.00m in 2024.
The demand for anti-coagulants in Malaysia is growing steadily due to an aging population and increasing prevalence of cardiovascular diseases.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Anti-Coagulants in Malaysia has been steadily increasing over the past few years.

Customer preferences: Patients in Malaysia are increasingly opting for Anti-Coagulants due to the rising incidence of cardiovascular diseases and stroke. The aging population and sedentary lifestyles have also contributed to the growing demand for Anti-Coagulants.

Trends in the market: The Anti-Coagulants market in Malaysia is witnessing a shift towards newer oral anticoagulants (NOACs) such as dabigatran, rivaroxaban, and apixaban. These NOACs have several advantages over traditional anticoagulants such as warfarin, including fewer drug interactions, no need for regular monitoring, and a lower risk of bleeding. This trend towards NOACs is expected to continue in the coming years.

Local special circumstances: One of the unique challenges in the Malaysian market is the lack of awareness about the importance of anticoagulation therapy among patients and healthcare providers. This has led to underutilization of Anti-Coagulants in the country. However, efforts are being made to increase awareness and improve access to Anti-Coagulants in Malaysia.

Underlying macroeconomic factors: The Malaysian government has been investing heavily in the healthcare sector, which has led to an increase in the availability and affordability of Anti-Coagulants in the country. Additionally, the growing middle class and increasing healthcare expenditure have also contributed to the growth of the Anti-Coagulants market in Malaysia.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.